Literature DB >> 9724170

Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine.

W D Heizer1, J L Peterson.   

Abstract

A 65-year-old man with Crohn's disease died of acute myeloblastic leukemia after treatment for 11.8 years with 6-mercaptopurine, 1.5 mg/kg/day (100 mg/day). On cytogenetic analysis, most of the malignant bone marrow cells had deletion of chromosome 7, the most frequently reported cytogenetic abnormality in chemotherapy-related acute leukemia. This finding, together with previous reports of acute leukemia and other malignancies following prolonged treatment with azathioprine or 6-mercaptopurine for nonmalignant conditions including inflammatory bowel disease, indicates that long-term use of these drugs for inflammatory bowel disease may increase the risk of malignancy. However, the magnitude of the risk is unknown.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724170     DOI: 10.1023/a:1018896006155

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

Review 1.  Review article: the medical management of Crohn's disease.

Authors:  E Elton; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  1996-02       Impact factor: 8.171

Review 2.  The association of inflammatory bowel disease and leukemia--coincidence or not?

Authors:  O Caspi; A Polliack; R Klar; D Ben-Yehuda
Journal:  Leuk Lymphoma       Date:  1995-04

3.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.

Authors:  D H Present; S J Meltzer; M P Krumholz; A Wolke; B I Korelitz
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

4.  Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome.

Authors:  A Iurlo; C Mecucci; A Van Orshoven; J L Michaux; M Boogaerts; L Noens; A Bosly; A Louwagie; H Van Den Berghe
Journal:  Cancer Genet Cytogenet       Date:  1989-12

5.  Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.

Authors:  H M Kantarjian; M J Keating; R S Walters; T L Smith; A Cork; K B McCredie; E J Freireich
Journal:  J Clin Oncol       Date:  1986-12       Impact factor: 44.544

6.  Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease.

Authors:  B I Korelitz; D J Adler; R A Mendelsohn; A L Sacknoff
Journal:  Am J Gastroenterol       Date:  1993-08       Impact factor: 10.864

Review 7.  Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease.

Authors:  A Forbes; N G Reading
Journal:  Aliment Pharmacol Ther       Date:  1995-10       Impact factor: 8.171

Review 8.  Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.

Authors:  E G Levine; C D Bloomfield
Journal:  Semin Oncol       Date:  1992-02       Impact factor: 4.929

9.  Chromosome pattern, occupation, and clinical features in patients with acute nonlymphocytic leukemia.

Authors:  F Mitelman; P G Nilsson; L Brandt; G Alimena; R Gastaldi; B Dallapiccola
Journal:  Cancer Genet Cytogenet       Date:  1981-11

10.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

View more
  5 in total

1.  Risk of haematopoietic cancer in patients with inflammatory bowel disease.

Authors:  J Askling; L Brandt; A Lapidus; P Karlén; M Björkholm; R Löfberg; A Ekbom
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

2.  Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate.

Authors:  Haruko Tashiro; Ryosuke Shirasaki; Mitsuho Noguchi; Moritaka Gotoh; Kazuo Kawasugi; Naoki Shirafuji
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

3.  Azathioprine-associated myelodysplastic syndrome in two patients with ulcerative colitis.

Authors:  Omer F Ahmad; Margaret G Keane; Sara McCartney; Asim Khwaja; Stuart L Bloom
Journal:  Frontline Gastroenterol       Date:  2013-03-20

Review 4.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Treatment-associated acute myeloid leukemia in a patient with Crohn's disease on 6-mercaptopurine.

Authors:  Koushik K Das; Ha Thanh Nishino; Andrew T Chan
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.